Presented by Christophe Le Tourneau, Head of Early Phase Clinical Trials & Head and Neck Cancer Groups, Department of Medical Oncology Institut Curie, France
With the emergence of drugs that target specific molecular alterations in the tumour, genomics has practically entered the oncology clinic.
Molecularly targeted agents have followed the same clinical development as cytotoxic agents and have been developed in selected tumour types. The occurrence of the same molecular alterations across various tumour types is well described.
This raises the question: should treatment decisions in the future be entirely based on molecular biology?
Fill in the form opposite to hear Christophe's presentation on the evidence and challenges for the implementation of precision medicine in oncology.